Publication Name	World Journal of Gastroenterology
Manuscript ID	73953
Country	China

Received	2021-12-10 06:46
Peer-Review Started	2021-12-10 06:49
To Make the First Decision
Return for Revision	2022-01-08 08:09
Revised	2022-01-14 13:42
Second Decision	2022-04-24 02:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-04-24 19:18
Articles in Press	2022-04-24 19:18
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-04-05 14:30
Typeset the Manuscript	2022-05-07 06:44
Publish the Manuscript Online	2022-05-27 11:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
Manuscript Source	Unsolicited Manuscript
All Author List	Yong-Bo Kang and Yue Cai
Funding Agency and Grant Number
Corresponding Author	Yong-Bo Kang, PhD, Associate Professor, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Wenhua Street, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com
Key Words	Gut microbiome; Immunotherapy; ICIs resistance; Probiotics; Faecal microbiota transplantion; Hepatocellular carcinoma; Prognosis
Core Tip	We read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that the gut microbiota is closely related to therapeutic effect of nivolumab. Future research should pay attention to the relationship between the gut microbiota and therapeutic effect of immune checkpoint inhibitors (ICIs) on advanced hepatocellular carcinoma and the way of regulating the gut microbiota to improve the therapeutic effect of ICIs.
Publish Date	2022-05-27 11:37
Citation	Kang YB, Cai Y. Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”. World J Gastroenterol 2022; 28(20): 2248-2250
URL	https://www.wjgnet.com/1007-9327/full/v28/i20/2248.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i20.2248

Full Article (PDF)	WJG-28-2248.pdf
Full Article (Word)	WJG-28-2248.docx
Manuscript File	73953_Auto_Edited-JJW-WangTQ.docx
Answering Reviewers	73953-Answering reviewers.pdf
Audio Core Tip	73953-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	73953-Conflict-of-interest statement.pdf
Copyright License Agreement	73953-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	73953-Language certificate.pdf
Peer-review Report	73953-Peer-review(s).pdf
Scientific Misconduct Check	73953-Bing-Wang JJ-2.png
Scientific Editor Work List	73953-Scientific editor work list.pdf